IBRX Responds to FDA Warning Over Misleading Cancer Drug Claims

The FDA issued a warning to ImmunityBio over misleading marketing claims for its Anktiva product; the company has outlined specific compliance fixes and corrective actions. Management stressed continued strong sales growth and expansion efforts, but the regulatory notice introduces near-term uncertainty until remediation is confirmed.

Analysis

The FDA issued a warning to ImmunityBio over misleading marketing claims for its Anktiva product; the company has outlined specific compliance fixes and corrective actions. Management stressed continued strong sales growth and expansion efforts, but the regulatory notice introduces near-term uncertainty until remediation is confirmed.